Anthony Buisson
Elite in Ulcerative Colitis

Anthony Buisson

Clermont-ferrand, FR 
Elite in Ulcerative Colitis
Clermont-ferrand, FR 
OverviewLocationsClinical Research

Overview

Anthony Buisson practices in Clermont-ferrand, France. Mr. Buisson is rated as an Elite expert by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Colitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 48 articles and participated in 8 clinical trials in the study of Ulcerative Colitis.

Gender
Male

Locations

Clermont-ferrand, France
Other Locations
Hôpital ST Eloi
Montpellier, France
Paris, France
Auvergny, 63000, France
Montfermeil, France
Lyon, France
Saint-etienne-de-valoux, France
CHU d'Amiens
Amiens, 80000, France
La Tronche, 38700, France
CHU De Saint Étienne, Rue Pointe Cadet, 42100, France
CHU Lyon Sud
Pierre-la-treiche, France
IBGC, UMR5095, 1 Rue Camille Saint Saëns, Bordeaux, 33000, France
Estaing, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Infliximab, Vedolizumab Injection
Study Phase: Phase 4
A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Biological, Other
Study Drug: Darvadstrocel Adipose Stem Cell Transplantation
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Phase 4
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Enrollment Status: Terminated
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Valganciclovir
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Golimumab
Study Phase: Phase 4
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drugs: Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Study Phase: Phase 4
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease
Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease
Enrollment Status: Unknown
Publish Date: July 09, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to Adherent-Invasive Escherichia Coli
Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to Adherent-Invasive Escherichia Coli
Enrollment Status: Completed
Publish Date: February 04, 2019
Intervention Type: Other
View 12 Less Clinical Trials

181 Total Publications

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
Journal: Journal of Crohn's & colitis
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Buisson's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile